文献速递肿瘤 PET/CT

68Ga-FAPI-04 PET 用于胃癌初始 N 和 M 分期的对比评估:与组织病理学和增强 CT 的对照研究

Comparative Evaluation of 68Ga-FAPI-04 PET for Initial N and M Staging in Gastric Cancer: A Study Against Histopathology and Contrast-Enhanced CT.
PubMed 文献 · Clin Nucl Med · 2025-04-07

回顾性纳入 62 例治疗前接受 68Ga-FAPI-04 PET/MRI 或 PET/CT 的胃癌患者,以淋巴结清扫后组织病理学为 N 分期金标准,比较 68Ga-FAPI-04 PET 与增强 CT 对区域淋巴结转移和远处转移的诊断效能;68Ga-FAPI-04 PET 在基于患者的 N 分期和 M 分期方面诊断性能与增强 CT 相当,但在显示远处转移方面优于增强 CT,可显示更多病灶或更大病灶范围。

要点

  • 68Ga-FAPI-04 PET 对胃癌基于患者的 N 分期诊断效能与增强 CT 相当。
  • 68Ga-FAPI-04 PET 对基于患者的 M 分期诊断效能与增强 CT 相当。
  • 68Ga-FAPI-04 PET 在显示腹膜、远处淋巴结、骨、肝和卵巢转移方面优于增强 CT。

核心结论

  • 68Ga-FAPI-04 PET 对胃癌基于患者的 N 分期和 M 分期诊断性能与增强 CT 相当,但在显示远处转移方面优于增强 CT。

研究设计与样本

  • 回顾性纳入治疗前接受 68Ga-FAPI-04 PET/MRI 或 PET/CT 的胃癌患者,共 62 例。
  • 以淋巴结清扫后组织病理学为 N 分期金标准,以组织病理学和随访数据为总体结局参考。

主要发现

  • 在 18 例接受 68Ga-FAPI-04 PET/MRI 和淋巴结清扫的患者中,共清扫 532 枚淋巴结;68Ga-FAPI-04 PET/MRI 与增强 CT 的灵敏度 28.3% 对 23.2%、特异度 99.8% 对 99.3%、准确率 86.5% 对 85.2%,所有 P > 0.05。
  • 55 例有区域淋巴结转移的患者中,68Ga-FAPI-04 PET 与增强 CT 的灵敏度 83.6% 对 87.3%、特异度 100% 对 85.7%、准确率 85.5% 对 87.1%,所有 P > 0.05。
  • 排除 3 例仅行腹部增强 CT 的患者后,59 例中 32 例有远处转移,基于患者 68Ga-FAPI-04 PET 与增强 CT 的灵敏度 100% 对 87.5%、特异度 92.6% 对 96.3%、准确率 96.6% 对 91.5%,所有 P > 0.05。
  • 68Ga-FAPI-04 PET 通过显示更多病灶或更大病灶范围,在检测腹膜、远处淋巴结、骨、肝和卵巢转移方面优于增强 CT。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficiency of 68Ga-FAPI-04 PET (PET/MRI or PET/CT) for N and M staging in gastric carcinoma and compare outcomes with histopathology and contrast-enhanced computed tomography (CECT). PATIENTS AND METHODS: Patients with gastric carcinoma who had undergone 68Ga-FAPI-04 PET/MRI or PET/CT before treatment were retrospectively enrolled. Histopathology post lymphadenectomy was the gold standard for N staging, while histopathology and follow-up data were the reference for overall outcomes. The diagnostic efficiency of 68Ga-FAPI-04 PET for detecting regional lymph node involvement and distant metastases was compared to that of CECT. RESULTS: Sixty-two patients were enrolled. In 18 patients who underwent 68Ga-FAPI-04 PET/MRI and lymphadenectomy, 532 lymph nodes were dissected. 68Ga-FAPI-04 PET/MRI showed similar sensitivity, specificity, and accuracy compared to CECT (28.3% vs. 23.2%, 99.8% vs. 99.3%, and 86.5% vs. 85.2%, all P > 0.05). Fifty-five patients had regional lymph node metastasis, 68Ga-FAPI-04 PET exhibited comparable diagnostic efficiency to CECT, with sensitivity of 83.6% versus 87.3%, specificity of 100% versus 85.7%, accuracy of 85.5% versus 87.1% (all P > 0.05). Excluding 3 patients with only abdominal CECT, 32 out of 59 patients had distant metastasis, with no significant differences in sensitivity, specificity, and accuracy between 68Ga-FAPI-04 PET and CECT based on patient (100% vs. 87.5%, 92.6% vs. 96.3%, and 96.6% vs. 91.5%, all P >0.05). Notably, 68Ga-FAPI-04 PET outperformed CECT in detecting peritoneal, distant lymph nodes, bone, liver, and ovarian metastases by visualizing more lesions or greater lesion extent. CONCLUSIONS: 68Ga-FAPI-04 PET exhibits comparable diagnostic performance to CECT for patient-based N staging and M staging of gastric cancer. However, it surpasses CECT in visualizing distant metastases.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fu Y, Qin C, Li M, et al. Comparative Evaluation of 68Ga-FAPI-04 PET for Initial N and M Staging in Gastric Cancer: A Study Against Histopathology and Contrast-Enhanced CT. Clin Nucl Med. 2025. PMID: 40179292. doi:10.1097/RLU.0000000000005795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。